Menarini of Italy paid $100 million to in-license China and Asia-Pacific rights for a liver cancer treatment developed by Germany's 4SC AG; Chongqing Lummy Pharma, with help from TVM's $50 million China BioPharma Capital I fund, announced a $40 million deal to in-license greater China rights for a cancer immunotherapy platform from Argos Therapeutics of the US; Shanghai Fosun Pharma raised $940 million in a private placement from eight institutional investors; Guided Therapeutics of the US signed an MOU for China distribution rights to a cervical cancer screening device; Jiangsu NHWA Pharma and its Israeli partner, D-Pharm Ltd., were approved to begin China clinical trials of their epilepsy treatment; PerkinElmer was granted CFDA approval to market a new prenatal/neo-natal genetic analyzing device; and Boston Scientific enlisted Suzhou's Frankenman Medical Equipment Company to provide training to China physicians in the use of BSX's endoscopic surgery devices.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
